EUCTR2010-022975-67-IT进行中（未招募）不适用
68Ga-DOTANOC as a PET tool to diagnose nueroendocrine tumors - ND
AZIENDA U.L.S.S. N.8 DI ASOLO0 个研究点开始时间: 2011年5月13日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Adult subjects (male and female) with recent diagnosis of neuroendocrine tumors (such as carcinoid and GEP tumors) before treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Normal volunteers, young people, pregnant women.
研究者
相似试验
进行中（未招募）
不适用
PET imaging of neuroendocrine tumoursEUCTR2012-002513-19-SEKarolinska University Hospital Solna
Unknown
1 期
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine TumorsNeuroendocrineNeuroendocrine CancerNeuroendocrine CarcinomaCarcinoid TumorIslet Cell TumorApudomaNeuroendocrine TumorCarcinoidNCT02038738Ochsner Health System250
No Longer Available
不适用
68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access TrialNeuroendocrine TumorsNCT02358018Memorial Sloan Kettering Cancer Center
已完成
2 期
68Ga-DOTATATE PET Scan in Neuroendocrine CancerNeuroendocrine CarcinomaNCT01396382Vanderbilt-Ingram Cancer Center97
进行中（未招募）
不适用
Investigation to understand the significance of a new nuclear medicine imaging technique (68Ga-DOTAOTC PET) for diagnosis of newly diagnosed or recurrent brain tumors originating in the arachnoid membrane (meningiomas)Based on the finding that meningiomas express somatostatin-receptor 2 (SSTR2), PET imaging with SSTR ligands like 68Ga-DOTATOC has been proposed as a more specific method. Currently, the role of SSTR-based imaging for meningioma diagnosis and treatment is still unclear. Therefore the accuracy of MRI and 68Ga-DOTATOC-PET for meningioma diagnosis at initial presentation, to determine residual tumor postoperatively and recurrence during follow-up will be investigated.EUCTR2013-002526-23-ATMedizinische Universität Innsbruck